Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1480365

GTEX

c9e308da-8dc0-5485-9b2a-d48af842c8e4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.486
  • HEDGEHOG_SIGNALING+0.347
  • PANCREAS_BETA_CELLS+0.298
  • MYOGENESIS+0.204
  • XENOBIOTIC_METABOLISM+0.182
  • ANGIOGENESIS+0.179
  • ESTROGEN_RESPONSE_LATE+0.165
  • SPERMATOGENESIS+0.164
  • ESTROGEN_RESPONSE_EARLY+0.163
  • OXIDATIVE_PHOSPHORYLATION+0.159

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.588
  • MYC_TARGETS_V1-0.462
  • E2F_TARGETS-0.435
  • INTERFERON_GAMMA_RESPONSE-0.432
  • G2M_CHECKPOINT-0.413
  • DNA_REPAIR-0.379
  • PROTEIN_SECRETION-0.357
  • MITOTIC_SPINDLE-0.349
  • TGF_BETA_SIGNALING-0.299
  • IL6_JAK_STAT3_SIGNALING-0.293

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1487321
brain-umap@2
GTEX—0.926
2SRR1396595
brain-umap@2
GTEX—0.920
3SRR1433431
brain-umap@2
GTEX—0.910
4SRR1421351
brain-umap@2
GTEX—0.907
5SRR603333
brain-umap@2
GTEX—0.896
6SRR1316297
brain-umap@2
GTEX—0.893
7SRR657635
brain-umap@2
GTEX—0.892
8SRR1418992
brain-umap@2
GTEX—0.890
9SRR1405007
brain-umap@2
GTEX—0.887
10SRR1453145
brain-umap@2
GTEX—0.882

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.486Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.347Inavolisib— uncovered
PANCREAS_BETA_CELLS0.298Cobimetinib— uncovered
MYOGENESIS0.204Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.182Inavolisib— uncovered
ANGIOGENESIS0.179Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.165Idelalisib— uncovered
SPERMATOGENESIS0.164Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.163Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.159Remibrutinib— uncovered
UV_RESPONSE_UP0.150Idelalisib— uncovered
APICAL_SURFACE0.149Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.099Inavolisib— uncovered
COAGULATION0.083Binimetinib— uncovered
UV_RESPONSE_DN0.080Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.079Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.069Inavolisib— uncovered
APICAL_JUNCTION0.067Inavolisib— uncovered
HYPOXIA0.060Idelalisib— uncovered
KRAS_SIGNALING_UP0.043Inavolisib— uncovered